Safety and immunogenicity of bivalent inactivated vaccine against haemorrhagic fever with renal syndrome in a phase II trial on healthy Chinese volunteers Online publication date: Wed, 27-Jun-2007
by Guan Mu Dong, Liang Han, An Qi, Wen Xue Liu, Yan Kong, Lihong H. Yang
International Journal of Biotechnology (IJBT), Vol. 9, No. 3/4, 2007
Abstract: We have developed a cell culture-derived, inactivated bivalent vaccine against both Haemorrhagic Fever with Renal Syndrome (HFRS) viruses 84 Fli (type I) and L99 (type II). This purified vaccine was tested in the clinical phase I/II trial in healthy non-infected adults in China. About 518 volunteers in Southern region and 650 volunteers from the Northern region of China were vaccinated. Volunteers then received one or two boosts at two weeks post-vaccination. No obvious side effects were observed among vaccinees after each inoculation. More than 87% of vaccinees have exhibited high neutralising antibody titers by Plaque Reducing Neutralising Test (PRNT) against both types I and II viruses and 100% positive seroconversion of IgG antibody by ELISA. These results indicate that our purified cell culture-derived bivalent vaccine is safe, well-tolerated and capable of inducing a protective immunity.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook